What Budget 2024 means for people affected by neuromuscular conditions so far
Additional measures have been unveiled that will impact a range of departments, the precise details of these measures are still in the process of becoming clear. We are currently working on providing a more extensive analysis of these actions, which will be accessible in the forthcoming weeks as we collect additional information.
Reimbursement Approval of Evrysdi® for the Treatment of Spinal Muscular Atrophy
On 1 September the HSE announced that Risdiplam (Evrysdi®) has been approved for reimbursement in Ireland. This makes Risdiplam the third SMA medicine available in Ireland, alongside Zolgensma and Spinraza.